New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
October 14, 2021 - The FDA approved UCB’s Vimpat (lacosamide), for the treatment of partial-onset seizures in patients 1 month of age and older.
Download PDF
Return to publications
